TrialCurveMSCs + basiliximab/CNI in steroid-resistant acute GVHD: reconstructed Kaplan–Meier curves
Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | J Hematol Oncol. 2022 Mar 7;15:22. doi: 10.1186/s13045-022-01240-4 |
|---|---|
| DOI | 10.1186/s13045-022-01240-4 |
| Registry | NCT02241018 |
| Phase | Phase 2, Phase 3 |
| Conditions | Acute Graft-versus-host Disease |
| Interventions | CD25 monoclonal antibody, calcineurin inhibitors, MSCs |
| Sponsor | Nanfang Hospital, Southern Medical University |
| Enrolment | 200 |
| Source licence | Figure published under CC BY 4.0 |
Overall survival — Randomized patients stratified by receipt of MSCs post-randomization; 8 control patients who crossed over to MSCs counted in control group (per caption)
From figure panel A · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: MSC group not reached; Control group 16.8 months. Survival at 18 months: MSC group 63%; Control group 50%. Hazard ratio MSC group vs Control group 0.66 (95% CI 0.43–1.01).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| MSC group | 99 | 36 | not reached |
| Control group | 99 | 50 | 16.8 |
- MSC group vs Control group: reconstructed HR 0.66 (95% CI 0.43–1.01)
Landmark survival (reconstructed)
| Time | MSC group | Control group |
|---|---|---|
| 6 mo | 68.7% | 61.4% |
| 12 mo | 65.6% | 52.2% |
| 18 mo | 63.3% | 49.6% |
| 24 mo | 63.3% | 48.3% |
| 36 mo | 63.3% | 48.3% |
| 48 mo | 63.3% | 48.3% |
| 60 mo | 63.3% | — |
Checks against the published figure
- hazard ratio (direction inferred): printed 0.67, reconstructed 0.659 pass
Failure-free survival — Randomized patients stratified by receipt of MSCs post-randomization; 8 control patients who crossed over to MSCs counted in control group (per caption)
From figure panel B · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: MSC group 11.2 months; Control group 6.0 months. Survival at 18 months: MSC group 43%; Control group 26%. Hazard ratio MSC group vs Control group 0.67 (95% CI 0.48–0.94).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| MSC group | 99 | 60 | 11.2 |
| Control group | 99 | 74 | 6.0 |
- MSC group vs Control group: reconstructed HR 0.67 (95% CI 0.48–0.94)
Landmark survival (reconstructed)
| Time | MSC group | Control group |
|---|---|---|
| 6 mo | 59.4% | 50.3% |
| 12 mo | 47.0% | 34.9% |
| 18 mo | 42.6% | 26.5% |
| 24 mo | 39.9% | 23.5% |
| 36 mo | 36.3% | 22.0% |
| 48 mo | 36.3% | 22.0% |
| 60 mo | — | — |
Checks against the published figure
- hazard ratio (direction inferred): printed 0.68, reconstructed 0.672 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Load these data in R or Python
# R
library(survival)
d <- read.csv("https://trialcurve.com/data/trials/mscs-plus-basiliximab-cni-in-steroid-resistant-acute-gvhd-1.csv")
survfit(Surv(time, event) ~ arm, data = d)
coxph(Surv(time, event) ~ arm, data = d)
# Python
import pandas as pd
from lifelines import KaplanMeierFitter
d = pd.read_csv("https://trialcurve.com/data/trials/mscs-plus-basiliximab-cni-in-steroid-resistant-acute-gvhd-1.csv")
for arm, g in d.groupby("arm"):
KaplanMeierFitter().fit(g.time, g.event, label=arm).plot_survival_function()
Suggested citation: J Hematol Oncol. 2022 Mar 7;15:22. doi: 10.1186/s13045-022-01240-4 doi:10.1186/s13045-022-01240-4. Reconstructed data: TrialCurve (2026), https://trialcurve.com/trials/mscs-plus-basiliximab-cni-in-steroid-resistant-acute-gvhd
Report a problem with these data
Related trials
- Mesenchymal stromal cells for steroid-resistant acute GVHD: Cumulative incidence of leukemia relapse; Non-relapse mortality (NRM); Overall survival; c
- ENDURE/CML-IX: Molecular relapse-free survival (MRFS); Re-achievement of MMR (probability of a first MMR
- Acalabrutinib vs chlorambucil + rituximab in CLL (Asian phase 3): BICR-assessed duration of response; BICR-assessed progression-free survival; Overall survi
- ADMYRE: Overall survival; Progression-free survival with PD confirmation by investigator's assessm
- AGILE (long-term follow-up): Overall survival
- AML18 (CPX-351 vs DA + gemtuzumab ozogamicin): Event free survival; Overall survival
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials